

Financial news for EPRS dated on 2016-07-25: UPDATE: Epirus Says All Co. Directors Resigned; CEO Scott Rocklage Resigned

Financial news for EPRS dated on 2016-07-25: UPDATE: Epirus Says, related to Ch. 7 Filing, Trustee Will Assume Control Over Assets, Liabilities of Co.

Financial news for EPRS dated on 2016-07-25: 8-K from Epirus Just Out; Shows Filing of Voluntary Petition for Relief Under Ch. 7 of Title 11 of US Bankruptcy Court

Financial news for EPRS dated on 2016-07-25: Epirus Shares Halted News Pending

Financial news for EPRS dated on 2016-07-05: Stocks Hitting 52-Week Lows

Financial news for EPRS dated on 2016-06-14: UPDATE: Epirus Biopharmaceutical To Receive Payment Of \$3.5M In Cash

Financial news for EPRS dated on 2016-06-14: Epirus Biopharmaceutical Enters Binding Agreement With Zakłady Farmaceutyczne, 'will sell to Polpharma all of the outstanding shares of EPIRUS Biopharmaceuticals'

Financial news for EPRS dated on 2016-05-16: Benzinga's Top Downgrades

Financial news for EPRS dated on 2016-05-16: Leerink Swann Downgrades EPIRUS Biopharmaceuticals to Market Perform

Financial news for EPRS dated on 2016-05-11: Decreasing Visibility: BTIG Downgrades EPRS To Neutral

Financial news for EPRS dated on 2016-05-11: BTIG Research Downgrades EPIRUS Biopharmaceuticals to Neutral

Financial news for EPRS dated on 2016-05-11: Wedbush Downgrades EPIRUS Biopharmaceuticals to Neutral

Financial news for EPRS dated on 2016-03-16: Leerink Swann Maintains Outperform on Epirus Biopharmaceuticals, Lowers PT to \$10.00

Financial news for EPRS dated on 2016-03-15: Epirus Q4 EPS (\$0.63) vs (\$0.56) est, Revenue \$285K vs \$230K est

Financial news for EPRS dated on 2016-03-01: Epirus Biopharmaceuticals To Sell \$30M Shares Of Common Stock

Financial news for EPRS dated on 2016-02-09: EPIRUS Biopharma Reports Initiation of Pivotal Global Phase 3 Study for BOW015: UNIFORM Study Builds on Prior Success of Phase 1, Phase 3 Studies

Financial news for EPRS dated on 2015-11-16: EPIRUS Biopharmaceuticals Provides Clinical Program Update on BOW015

Financial news for EPRS dated on 2015-09-21: Epirus Biopharmaceuticals CEO Munshi Buys 10,000 Shares @\$5.99/Share -Form 4

Financial news for EPRS dated on 2015-09-09: EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and Capabilities Through Acquisition of Bioceros

Financial news for EPRS dated on 2015-08-07: EPIRUS Reports Q2 Loss \$0.65 May Not Compare

Financial news for EPRS dated on 2015-07-14: Tuesday's Mid-Day Movers: Iran's Nuclear Deal Reached; Micron Technology Bid, Box Inc And More

Financial news for EPRS dated on 2015-07-14: EPIRUS Biopharma Announces Collaboration with Polpharma, Will Recieve ~\$30M For Clinical Development Costs

Financial news for EPRS dated on 2015-06-10: EPIRUS Biopharma Announces Preliminary Data Which Indicates Safety of BOW015

Financial news for EPRS dated on 2015-06-09: EPIRUS Biopharma Decreasing Number Of Authorized Shares From 300M To 70M

Financial news for EPRS dated on 2015-05-28: Top 4 Small-Cap Stocks In The Biotechnology Industry With The Highest EPS

Financial news for EPRS dated on 2015-05-27: BTIG Research Initiates Coverage on Epirus Biopharmaceuticals at Buy, Announces \$15.00 PT

Financial news for EPRS dated on 2015-03-23: EPIRUS Reports Q4 EPS \$(0.80) vs. Est. \$(0.99), Rev. 4k; Revenue Estimate Not Available

Financial news for EPRS dated on 2015-02-06: 5am Partners III Buys 400,000 Shares of Epirus Biopharmaceuticals @\$5.00/Share -Form 4

Financial news for EPRS dated on 2015-01-30: US Stock Futures Dip Ahead Of GDP Data

Financial news for EPRS dated on 2015-01-30: EPIRUS Prices \$48 Million Public Offering of Common Stock

Financial news for EPRS dated on 2015-01-27: Morning Market Losers

Financial news for EPRS dated on 2014-12-02: EPIRUS Biopharmaceuticals Remicade Biosimilar, Infimab, Launches In India

Financial news for EPRS dated on 2014-11-17: EPIRUS Biopharmaceuticals Phase 3 Study of BOW015, a biosimilar infliximab, to be Presented as a Late Breaking Poster at the American College of Rheumatology Annual Meeting Business Wire - Nov 17 08:00 EDT

Financial news for EPRS dated on 2014-09-25: EPIRUS and Livzon Mabpharm, Inc. Enter Collaboration Agreement for China

Financial news for EPRS dated on 2014-09-23: Morning Market Movers

Financial news for EPRS dated on 2014-09-23: Epirus Reports Positive 58 Week Follow Up Data for BOW015 for Treatment of RA, Study Met Primary Endpoint of ACR20 Response

Financial news for EPRS dated on 2014-09-23: EPIRUS Announces Positive 58 Week Follow up Data for BOW015

Financial news for EPRS dated on 2014-09-15: EPIRUS' Remicade Biosimilar Receives Final Approvals in India

Financial news for EPRS dated on 2014-08-05: Livzon Mabpharm Reports 12.14% Passive Stake In Epirus Biopharmaceuticals as of July 15